227 related articles for article (PubMed ID: 15643230)
1. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia.
Vela-Navarrete R; Escribano-Burgos M; Farré AL; García-Cardoso J; Manzarbeitia F; Carrasco C
J Urol; 2005 Feb; 173(2):507-10. PubMed ID: 15643230
[TBL] [Abstract][Full Text] [Related]
2. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Plosker GL; Brogden RN
Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
[TBL] [Abstract][Full Text] [Related]
3. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.
Vela Navarrete R; Garcia Cardoso JV; Barat A; Manzarbeitia F; López Farré A
Eur Urol; 2003 Nov; 44(5):549-55. PubMed ID: 14572753
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.
Bernichtein S; Pigat N; Camparo P; Latil A; Viltard M; Friedlander G; Goffin V
Prostate; 2015 May; 75(7):706-22. PubMed ID: 25683150
[TBL] [Abstract][Full Text] [Related]
5. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
[TBL] [Abstract][Full Text] [Related]
7. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
Buck AC
J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia.
Pytel YA; Vinarov A; Lopatkin N; Sivkov A; Gorilovsky L; Raynaud JP
Adv Ther; 2002; 19(6):297-306. PubMed ID: 12665050
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens.
Stepanov VN; Siniakova LA; Sarrazin B; Raynaud JP
Adv Ther; 1999; 16(5):231-41. PubMed ID: 10915398
[TBL] [Abstract][Full Text] [Related]
11. The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens.
Giannakopoulos X; Baltogiannis D; Giannakis D; Tasos A; Sofikitis N; Charalabopoulos K; Evangelou A
Adv Ther; 2002; 19(6):285-96. PubMed ID: 12665049
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
13. The combination of Serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth.
Altavilla D; Bitto A; Polito F; Irrera N; Marini H; Arena S; Favilla V; Squadrito F; Morgia G; Minutoli L
J Urol; 2011 Oct; 186(4):1524-9. PubMed ID: 21855911
[TBL] [Abstract][Full Text] [Related]
14. [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon].
Sivkov AV; Kudriavtsev IuV; Medvedev AA; Razumov SV; Kochetov SA
Urologiia; 2004; (5):10-6. PubMed ID: 15560155
[TBL] [Abstract][Full Text] [Related]
15. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
[TBL] [Abstract][Full Text] [Related]
16. Hexanic Extract of Serenoa repens (Permixon
Blair HA
Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia.
Grasso M; Montesano A; Buonaguidi A; Castelli M; Lania C; Rigatti P; Rocco F; Cesana BM; Borghi C
Arch Esp Urol; 1995; 48(1):97-103. PubMed ID: 7537488
[TBL] [Abstract][Full Text] [Related]
18. [Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms].
Amdii RE; Al' Shukri AS
Urologiia; 2018 May; (2):114-120. PubMed ID: 29901305
[TBL] [Abstract][Full Text] [Related]
19. Serenoa repens for benign prostatic hyperplasia.
Wilt T; Ishani A; Stark G; MacDonald R; Mulrow C; Lau J
Cochrane Database Syst Rev; 2000; (2):CD001423. PubMed ID: 10796790
[TBL] [Abstract][Full Text] [Related]
20. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial].
Glemain P; Coulange C; Billebaud T; Gattegno B; Muszynski R; Loeb G;
Prog Urol; 2002 Jun; 12(3):395-403; discussion 404. PubMed ID: 12189745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
